Drug Trial Radar · NCT05489211
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
454
Planned (sponsor's estimate)
Start
Sep 6, 2022
Primary completion
Oct 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Aug 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Conditions
- Endometrial Cancer
- Gastric Cancer
- Metastatic Castration-resistant Prostate Cancer
- Ovarian Cancer
- Colorectal Cancer
- Urothelial Cancer
- Biliary Tract Cancer
Interventions
Datopotamab deruxtecan (Dato-DXd)Drug
Intravenous (IV) Antibody drug conjugate
CapecitabineDrug
Administered orally
5-FluorouracilDrug
Administered as an IV
VolrustomigDrug
Administered as an IV
CarboplatinDrug
Administered as an IV
BevacizumabDrug
Administered as an IV
RilvegostomigDrug
Administered as an IV
Prednisone/ prednisoloneDrug
Administered orally
CisplatinDrug
Administered as an IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: From baseline to progressive disease or death (approximately 1 year)
- The number of subjects with adverse events/serious adverse eventsTime frame: Throughout the treatment and the safety follow-up period 28 [+ 7] days after the discontinuation of all study interventions, except durvalumab, nivolumab, and bevacizumab for which it will be 90 [+ 7] days (approximately 1 year)
- PSA50 response (Substudy 3 only)Time frame: From baseline to PSA response evaluated according to the PCWG3 criteria (approximately 1 year)
- Progression free survival (PFS) response (Substudy 4C only)Time frame: From baseline to progressive disease or death (approximately 1 year)
Locations
96 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California · Recruiting
Research Site
San Diego, California · Withdrawn
Research Site
Santa Rosa, California · Recruiting
Research Site
Muncie, Indiana · Withdrawn
Research Site
Kansas City, Kansas · Withdrawn
Research Site
Boston, Massachusetts · Withdrawn
Research Site
Boston, Massachusetts · Completed
Research Site
Grand Rapids, Michigan · Recruiting
Research Site
East Brunswick, New Jersey · Recruiting
Research Site
Albuquerque, New Mexico · Recruiting
Research Site
Commack, New York · Recruiting
Research Site
Cincinnati, Ohio · Recruiting
Research Site
Columbus, Ohio · Recruiting
Research Site
Portland, Oregon · Withdrawn
Research Site
Nashville, Tennessee · Recruiting
Research Site
Nashville, Tennessee · Withdrawn
Research Site
Houston, Texas · Recruiting
Research Site
Madison, Wisconsin · Recruiting
Research Site
Toronto, Ontario, Canada · Withdrawn
Research Site
Toronto, Ontario, Canada · Completed
Research Site
Montreal, Quebec, Canada · Withdrawn
Research Site
Montreal, Quebec, Canada · Completed
Research Site
Québec, Quebec, Canada · Active not recruiting
Research Site
Changsha, China · Withdrawn
Research Site
Chongqing, China · Withdrawn
Research Site
Guangzhou, China · Completed
Research Site
Guangzhou, China · Recruiting
Research Site
Guangzhou, China · Withdrawn
Research Site
Hangzhou, China · Recruiting
Research Site
Hefei, China · Withdrawn
Research Site
Shanghai, China · Recruiting
Research Site
Shanghai, China · Not yet recruiting
Research Site
Shenyang, China · Withdrawn
Research Site
Wuhan, China · Withdrawn
Research Site
Wuhan, China · Withdrawn
Research Site
Xi'an, China · Withdrawn
Research Site
Zhengzhou, China · Recruiting
Research Site
Bordeaux, France · Recruiting
Research Site
Lyon, France · Recruiting
Research Site
Marseille, France · Withdrawn
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.